BioSpace News Archive

Hutchison China MediTech Limited will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).

Researchers have developed a technique that is capable of eliminating replication-competent HIV-1 DNA from the genomes of living animals.

In addition to the states agreeing to pause lawsuits, the FDA accepted Insys’ NDA for an opioid overdose medication.

According to a University College London (UCL) report, British researchers are being shut out of major European research partnerships because of concerns over a no-deal Brexit.

Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.

The rising cost of healthcare has been a hot topic of discussion as of late throughout the United States, with many presidential candidates using it as a selling point of their campaign.

Shares of Karyopharm Therapeutics have skyrocketed more than 36% after the U.S. Food and Drug Administration approved the Newton, Mass.-based company’s treatment for multiple myeloma.

MorphoSys AG announced that its licensing partner GSK reported in a press release earlier the start of a phase 3 clinical development program with otilimab in rheumatoid arthritis.

Anahit International Corp. has licensed a patent from the University of Guelph to biosynthesize Cannflavin A and B outside of the cannabis plant.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.